Please use this identifier to cite or link to this item: http://hdl.handle.net/10773/34619
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlmeida, Catarina A. S.pt_PT
dc.contributor.authorSilva, Luís C. V.pt_PT
dc.contributor.authorSilva, Maria Carolinapt_PT
dc.contributor.authorNeves, Márcia C.pt_PT
dc.contributor.authorFreire, Mara G.pt_PT
dc.date.accessioned2022-09-15T18:24:27Z-
dc.date.available2022-09-15T18:24:27Z-
dc.date.issued2021-
dc.identifier.urihttp://hdl.handle.net/10773/34619-
dc.description.abstractAvian immunoglobulin Y (IgY), present in the chicken egg yolk, has potential to be used as a biopharmaceutical. Compared to its mammalian analogous immunoglobulin G (IgG), IgY presents advantages, namely high binding avidity and immunogenicity, and their recovery by a non-invasive method at high yields. The amount of IgY obtained from an egg is equal to that from 200-300 mL of mammalians blood, being possible for a chicken produce 17-35 g of total IgY. By being a polyclonal antibody, IgY recognize more epitopes on an antigen. Therefore, IgY has various applications, such as the treatment of several diseases. However, IgY derives from a complex media, making difficult their recovery at high purity and yields. Also, IgY is highly labile to changes in temperature, ionic strength, and pH, being difficult to preserve along time. These two drawbacks restrict their use as biopharmaceuticals. In this work, IgY antibodies were isolated from the yolk of commercial chicken eggs and purified by two precipitation steps. Their stability was assessed by Circular Dichroism Spectroscopy (CD) under 1-3 weeks of storage at -20 ºC, with and without sucrose and sorbitol, to evaluate their use as stabilizers agents. The purity level, concentration and percentage of formed aggregates were determined by Size Exclusion- High Performance Liquid Chromatography (SEC-HPLC), and the protein profile revealed by dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Novel bio-based compounds have been identified as promising stabilizers to improve the stability of IgY antibodies, paving the way for their use as excipients in IgY therapeutic formulations.pt_PT
dc.language.isoengpt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F50011%2F2020/PTpt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F50011%2F2020/PTpt_PT
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/899921/EUpt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/CEEC IND 2017/CEECIND%2F00383%2F2017%2FCP1459%2FCT0031/PTpt_PT
dc.rightsopenAccesspt_PT
dc.titleBiocompatible excipients to improve the stability of avian immunoglobulin Y (IgY) antibodies: paving the way for their use as biopharmaceuticalspt_PT
dc.typeconferenceObjectpt_PT
dc.description.versionpublishedpt_PT
dc.peerreviewedyespt_PT
ua.event.date6-7 Outubro, 2021pt_PT
degois.publication.firstPage45pt_PT
degois.publication.titleJornadas CICECO 2021 - Advancing Science Shaping Societypt_PT
Appears in Collections:CICECO - Comunicações
DQ - Comunicações

Files in This Item:
File Description SizeFormat 
Biocompatible excipients....pdf136.45 kBAdobe PDFView/Open


FacebookTwitterLinkedIn
Formato BibTex MendeleyEndnote Degois 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.